^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
Published date:
03/31/2021
Excerpt:
Among the 67 patients, 8 (11.9%) achieved partial response and a median progression-free survival (PFS) of 4.8 months...PD-L1 positive tumours exhibited a poorer response to pazopanib treatment than the PD-L1 negative tumours (0% vs 14.8%, P = 0.07). PD-L1-positive tumours had significantly shorter PFS than the PD-L1-negative tumours (median PFS 2.8 vs 5.1 months, P = 0.003), and PD-L1 positivity was an independent predictor of poor response to pazopanib treatment...
DOI:
10.1186/s12885-021-08069-z
